E
Cambridge from Bay Bay Boston

An in-depth look at Neon’s updated neoantigen vaccine data

Insights on the updated phase 1b clinical data evaluating Neon's personalized vaccine NEO-PV-01 in combination with nivolumab in advanced cancers?

July 17, 2019
E

mRNA – the language of life

Can mRNA disrupt cancer therapy and boost responses beyond what we see with checkpoint therapy?

July 3, 2019
E

Chipping away at cancer

Gritstone have evolved from start-up biotech to clinical stage oncology company. We catch up with them and discuss their latest progress.

April 25, 2019
E

What did we learn from Neon at ESMO18?

Initial results from the neon NEO-PV-01 phase 1B trial presented by Dr Patrick Ott

October 30, 2018
E

New developments in neoantigen vaccines

A look a progress on NeoVax in GBM, RNA vaccines and even a novel CAR T cell therapy with a difference.

October 8, 2018
E

Iraj Ali leads the way at Achilles Therapeutics

Achilles Therapeutics is an emerging biotech in the cell therapy space that is based on truncal neoantigens

October 31, 2018
E

How Charles Swanton plans to revolutionize treatment of Lung and Renal cancers

What can we learn from the TRACERx studies in lung and renal cancers? Quite a lot, it seems...

April 26, 2018
E

The Future of Cancer Vaccines Part 5 – An Interview with Prof George Coukos

A look at the latest developments in cancer immunotherapy in ovarian cancer, with a particular focus on neoepitopes and cancer vaccines.

October 3, 2017
E

The Future of Cancer Vaccines Part 4 – An Interview with Prof Kees Melief

Interview with Prof Kees Melief, CSO ISA Immune System Activation Pharmaceuticals

October 2, 2017
E

The Future of Cancer Vaccines Part 3 – Interview with Prof Ugur Sahin

A look at Ugur Sahin's BioNTech and personalized mRNA vaccines

September 28, 2017
E

The Future of Cancer Vaccines Part 2 – interview with Dr Ira Mellman

Genentech have several cancer vaccine collaborations in place, where do they see the future going in this niche?

September 27, 2017
E

The Future of Cancer Vaccines – An Interview with Dr Cathy Wu

Part 1 of a new mini-series on cancer vaccines. This one covers an update on Neon's neoantigen approach...

September 26, 2017
E

On Gritstone and neoantigens

A look at a promising biotech in the neoantigen space - what's their approach and how might it fare?

May 4, 2017
E
View of Cambridge and Charles River

Does Neon Therapeutics lead the Neoantigen field?

Update on Neon Tx as they move into commercial new product development with their neoantigen platform.

January 13, 2017
E
Professor Ton Schumacher at CIML40

Is Targeting Neoantigens the Next Frontier in Cancer Immunotherapy?

Interview with Prof Ton Schumacher at scientific meeting to celebrate 40 years of Centre d’Immunologie de Marseille-Luminy (CIML).

September 22, 2016
E

NEON shines the light on Neoantigen targeted Cancer Immunotherapy

Cary Pfeffer of Third Rock Ventures describes how a novel neoantigen vaccine in academia transitioned into a commercial company with exciting prospects...

August 11, 2016
E

Can neoantigen vaccines make a difference in cancer research?

This is the second in our mini-series on neoantigens and looks at whether neoantigen based cancer vaccines can make a difference in the treatment of solid tumors.

August 10, 2016
E

What are neoantigens and why do they matter in cancer immunotherapy?

A primer on neoantigens and their importance in cancer research

August 9, 2016
E

George Coukos Drives Novel Ovarian Cancer Immunotherapies Forward

How can we improve T cell trafficking in ovarian cancer? Professor Coukos highlights numerous ways this could be achieved!

May 16, 2016
E

Adoptive Cell Therapy: An Interview with Dr Steven Rosenberg

We know that TILs can be effective in advanced melanoma, but what about common epithelial solid tumours? Can it work in these cancers too? Find out from Dr Rosenberg's latest work what's happening...

August 12, 2015